SYGNIS AG

euro adhoc: LION bioscience AG
Mergers - Acquisitions - Takeovers
Ad-hoc release LION bioscience confirms take-over bid of Hopp family (DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG)

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 05.07.2006 Heidelberg, July 5, 2006 - LION bioscience received today the information that two investment-companies of the Hopp family, DH-Capital GmbH & Co. KG und OH Beteiligungen GmbH & Co. KG, will make a voluntary bid to acquire all shares of LION bioscience AG at a price of EUR 1.82 per share. This decision is to be seen before the background of the contract signed by LION bioscience AG today to acquire SYGNIS Bioscience mbH & Co. KG, owned by the majority of the investment-company of the Hopp familiy. In this transaction, LION bioscience AG will pay in shares using the authorized capital of the company. Furthermore, as both investment companies of the Hopp family committed further capital inflow into LION bioscience AG, it is to be expected that they will further increase their stake in LION. For further information, please contact: |Peter Willinger |Dr. Franz-Werner Haas | |Chief Executive Officer |General Counsel | |Tel: +49 (0) 6221-4038 293 |Tel: +49 (0) 6221-4038 340 | |Email: |Email: | |peter.willinger@lionbioscience.com |franz.werner.haas@lionbioscience.c| | |om | | | | ### Except for the historical information contained herein, the matters set forth in this press release are forward looking. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company's targets for fiscal year. ### end of announcement euro adhoc 05.07.2006 21:40:19 -------------------------------------------------------------------------------- ots Originaltext: LION Bioscience AG Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Stephan Trautvetter Director Finance & Accounting Telefon: +49(0)6221 4038 476 E-Mail: stephan.trautvetter@lionbioscience.com Branche: Biotechnology ISIN: DE0005043509 WKN: 504350 Index: CDAX, Prime All Share, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime standard New York / ADR Börse Berlin-Bremen / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade

Das könnte Sie auch interessieren: